No phaseCompletedAge-related condition
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
- Sponsor
- LumiThera, Inc. (Industry)
- Enrolment
- 100 enrolled
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Valeda Light Delivery System; Valeda Light Delivery System Sham Mode
- Ages
- adults, older adults
- Registry
- NCT04065490
Full record on ClinicalTrials.gov
From the registry
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. Alcon Research, LLC, acquired LumiThera in September 2025.
Primary outcomes
- Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21
History
Results posted
Last registry update
Study completion
Primary completion
Started
Registered